肿瘤细胞治疗研究
英文原题：Chimeric antigen receptor T-cell therapy for relapsed and refractory thyroid cancer.
该患者终于在3个月时达到部分缓解，且对该方案耐受良好。
大多数甲状腺癌患者的预后极佳，但对于晚期或转移性甲状腺癌患者，仍缺乏有效的治疗手段。嵌合抗原受体（CAR）T细胞疗法在血液系统恶性肿瘤中取得了显著成就，但在实体瘤中疗效有限。在本报告中，我们展示了一例复发难治性甲状腺癌患者接受 TSHR + CD19 CAR-T 治疗的情况，该疗法是两种第二代 CAR-T 分子的联合，同时靶向 TSHR 和 CD19。该患者最终在 3 个月时达到部分缓解，且对该方案耐受良好。我们的研究表明，CAR-T 疗法可能是治疗复发难治性甲状腺癌的一种可行途径。
The prognosis of most thyroid cancer patients is excellent, but for those with advanced or metastatic thyroid cancer, effective treatments are still lacking. Chimeric antigen receptor (CAR) T-cell therapy has gained remarkable achievements in hematologic malignancy but shown limited efficacy in solid tumors. In this report, we showed a relapsed and refractory thyroid cancer patient treated with TSHR + CD19 CAR-T, a combination of two 2nd generation CAR-T molecules targeting both TSHR and CD19. This patient finally achieved partial remission at 3 months and was tolerate well to the regimen. Our study suggested that the CAR-T therapy could be a feasible way in treating relapsed and refractory thyroid cancer.
MEMBER ACCOUNT
登录成功会直接打开下一页。
